Therapy for recurrent malignant glioma in adults

References

• Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1995–1999. Central Brain Tumor Registry of the United States (2002).
   Google Scholar
• Kleihues P, Cavenee WK. World Health Organization Classification of Tumors: Pathology and Genetics of TUMOUTS of the Nervous System. IARC Press, Lyon, France (2000).
   Google Scholar
• Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumors in adults. Lancet 361,323–331 (2003).
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP Van Den Bent MJ et al Concomitant and adjuvant temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme. Conclusive results of a Randomized Phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group. Proc. Am. Soc. Clin. Oncol (2004) (Abstract 2).
   Google Scholar
• ••Landmark study showing for the first timethat adjuvant chemotherapy with temozolomide improves survival in patients with glioblastoma multiforme (GBM).
   Google Scholar
• Stupp R, Dietrich P-Y, Kraljevic SO et al Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. j Clin. Oncol 20, 1375–1382 (2002).
   PubMed Web of Science ®Google Scholar
• •Phase II study showing benefit of concomitant temozolomide with radiation therapy.
   Google Scholar
• Brandes AA. State-of-the-art treatment of high-grade brain tumors. Semin. Oncol 30, 4–9 (2003).
   PubMed Web of Science ®Google Scholar
• Stupp R, Regg C. New drugs and combinations for malignant glioma.Forum (Genova)13,61–75 (2003).
   PubMedGoogle Scholar
• Fine HA, Dear KBG, Loeffler JS, Black PM, Canellos GP Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer71, 2585–2597 (1993).
   PubMed Web of Science ®Google Scholar
• Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet 359, 1011–1018 (2002).
   PubMed Web of Science ®Google Scholar
• Van Rijn J, Heimans JJ, van der Berg J et al Survival of human glioma cells treated with various combinations of temozolomide and x-rays. Int.j Radiat. Oncol Biol. Phys. 47, 779–784 (2000).
   PubMed Web of Science ®Google Scholar
• Westphal M, Hilt DC, Bortey E et al A Phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel° wafers) in patients with primary malignant glioma. Neurooncology5, 79–88 (2003).
   PubMed Web of Science ®Google Scholar
• Levin VA, Leibel SA, Gutin PH. Neoplasms of the central nervous system. In: Cancer: Principles & Practice of Oncology. DeVita VT, Hellman S, Rosenberg SA (Eds), Lippincott Williams & Wilkins, PA, USA, 2100–2103 (2001).
   Google Scholar
• Galanis E, Buckner JC. Chemotherapy for high-grade gliomas. BE j Cancer 82, 1371–1380 (2000).
   Web of Science ®Google Scholar
• Nieder C, Grosu AL, Molls M. A comparison of treatment results for recurrent malignant gliomas. Cancer Treat. Rev 26,397–409 (2000).
   PubMed Web of Science ®Google Scholar
• •Comprehensive review of standard therapy for recurrent glioma.
   Google Scholar
• Tatter SB. Recurrent malignant glioma in adults. CUTE Treat. Options Oncol 23, 509–24 (2002).
   Google Scholar
• Wen PY, Kesari S. Malignant gliomas. Curr: Neural Neumsci. Rep. 4,218–227 (2004).
   Google Scholar
• •Recent review of the treatment of malignant glioma.
   Google Scholar
• Barker FG II, Chang SM, Gutin PH et al. Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgei y42, 709–720 (1998).
   PubMed Web of Science ®Google Scholar
• Keles GE, Lamborn KR, Chang SM, Prados MD, Berger MS. Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastoma multiforme who are undergoing chemotherapy. J. Neurosurg: 100,41-46 (2004).
   Google Scholar
• Hochberg PH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neumlogy 30,907–911 (1980).
   PubMed Web of Science ®Google Scholar
• Kim HK, Thornton AF, Greenberg HS et al. Results of re-irradiation of primary intracranial neoplasms with three-dimensional conformal therapy. Am. J Clin. Oncol 20,358–363 (1997).
   PubMed Web of Science ®Google Scholar
• Hayat K, Jones B, Bisbrown G et al. Retreatment of patients with intracranial gliomas by external beam radiotherapy and cytotoxic chemotherapy. Clin. Oncol (1?. Coll. Radial) 9,158–163 (1997).
   Google Scholar
• Landy HJ, Feun L, Schwade JG et al Retreatment of intracranial gliomas. South Med 87,211–214 (1994).
   Google Scholar
• Fiveash JB, Spencer SA. Role of radiation therapy and radiosurgery in glioblastoma multiforme. Cancer 1 9,222–229 (2003).
   Google Scholar
• McDermott MW, Sneed PK, Gutin PH. Interstitial brachytherapy for malignant brain tumors. Semin. Surg. Oncol 14, 79–87 (1998).
   Google Scholar
• Shrieve DC, Alexander E III, Wen PY et al Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery36, 275–282 (1995).
   PubMed Web of Science ®Google Scholar
• Florell RC, Macdonald DR, Irish WD et al Selection bias, survival and brachytherapy for glioma. I Neurosurg. 76,179–183 (1992).
   PubMed Web of Science ®Google Scholar
• Selker RG, Shapiro WR, Burger P et al The Brain Tumor Co-operative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery51, 343–355 (2002).
   PubMed Web of Science ®Google Scholar
• Patel S, Breneman JC, Wamick RE et al Permanent iodine-125 interstitial implants for the treatment of recurrent glioblastoma multiforme. Neurasurgeiy46,1123–1128 (2000).
   PubMed Web of Science ®Google Scholar
• Larson DA, Suplica JM, Chang SM et al Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme. Neumoncology6, 119–126 (2004).
   PubMed Web of Science ®Google Scholar
• Tatter SB, Shaw EG, Rosenblum ML et al An inflatable balloon catheter and liquid 1251 radiation source (GliaSite° Radiation Therapy System) for treatment of recurrent malignant glioma: multicenter safety and feasibility trial. J. Neurosurg. 99,297-303 (2003).
   Google Scholar
• Papagikos MA, Rossi PJ, Bartley A et al. Results of stereotactic radiosurgery and Gliasite brachytherapy for recurrent glioblastoma multiforme. Neumoncology5, 344 (2003) (Abstract RT–08).
   Google Scholar
• Roberge D, Souhami L. Stereotactic radiosurgery in the management of intracranial gliomas. 7chnol. Cancer Res. Brat. 2,117-125 (2003).
   Google Scholar
• Cho KH, Hall WA, Gerbi BJ et al Single dose versus fractionated stereotactic radiotherapy for recurrent high-gradegliomas. Int. J. Radiat. Oncol. Biol. Phys. 45, 1133–1141 (1999).
   PubMed Web of Science ®Google Scholar
• •Recent review of stereotactic radiosurgery and stereotactic radiotherapy in glioma.
   Google Scholar
• Hall WA, Djalilian HR, Sperduto PW et al Stereotactic radiosurgery for recurrent malignant gliomas. I Clin. Oncol 13, 1642–1648 (1995).
   PubMed Web of Science ®Google Scholar
• Larson DA, Prados M, Lamborn KR et al. Phase II study of high central dose gamma knife radiosurgery and marimastat in patients with recurrent malignant glioma. Int. J Radiat. Oncol. Biol. Phys. 54, 1397–1404 (2002).
   PubMed Web of Science ®Google Scholar
• Barth RE A critical assessment of boron neutron capture therapy: an overview. Neumoncol 62,1–5 (2003).
   PubMed Web of Science ®Google Scholar
• Busse PM, Harling OK, Palmer MR et al A critical examination of the results from the Harvard-MIT NCT program Phase I clinical trial of neutron capture therapy for intracranial disease. J. Neurooncol 62, 111–121 (2003).
   PubMed Web of Science ®Google Scholar
• Zalutsky MR. Targeted radiotherapy of brain tumors. Br. Cancer 90,1469–1473 (2004).
   Google Scholar
• Reardon DA, Akabani G, Coleman R et al. Phase II trial of murine 131I-labeled antitenascin monoclonal antibody 81c6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. I Clin. Oncol 20,1389–1397 (2002).
   Google Scholar
• Prados M. Temozolomide in combination with other cytotoxic agents. Semin. Oncol 28,24–33 (2001).
   PubMed Web of Science ®Google Scholar
• Rosenthal MA, Ashley DL, Cher L. BCNU as second line therapy for recurrent high-grade glioma previously treated with temozolomide. I Clin. Neuroscl11, 374–375 (2004).
   Google Scholar
• Kappelle AC, Postma TJ, Taphoorn MJ et al PCV chemotherapy for recurrent glioblastoma multiforme. Neurology 56, 118–120 (2001).
   PubMed Web of Science ®Google Scholar
• Newton HB, Junck L, Bromberg J, Page MA, Greenberg HS. Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure. Neurology 40, 1743–1746 (1990).
   Google Scholar
• Jeremic B, Grujicic D, Jevremovic S et al Carboplatin and etoposide regimen for recurrent malignant glioma: a Phase II study.I Clin. Oncol 10,1074–1077 (1992).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Tsao-Wei DD. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. Cancer 100, 1213–1220 (2004). Fulton D, Urtasun R, Forsyth P. Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. I Neurooncol 27,149–155 (1996).
   Google Scholar
• Basso U, Lonardi S, Brandes AA. Is infra-arterial chemotherapy useful in high-grade gliomas? Expert Rev Anticancer Ther 2, 507–519 (2002).
   PubMedGoogle Scholar
• •Good review of intra-arterial chemotherapy.
   Google Scholar
• Brandes AA, Palmisano V, Pasetto LM, Basso U, Monfardini S. High-dose chemotherapy with bone marrow rescue for high-grade gliomas in adults. Cancer Invest. 19,41–48 (2003).
   Google Scholar
• Abrey LE, Childs BH, Paleologos N et al High-dose chemotherapy with stem cell rescue for anaplastic oligodendroglioma. Neurooncol 65,127–134 (2003).
   PubMed Web of Science ®Google Scholar
• Robins HI, Chang SM, Prados MD et al A Phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study. Neumoncology4, 109–114 (2002).
   PubMed Web of Science ®Google Scholar
• Prados MD, Schold SC, Fine HA et al A randomized, double-blind, placebo-controlled Phase II study of RN/IP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neurooncology5, 96–103 (2003).
   PubMed Web of Science ®Google Scholar
• Hochberg F, Prados M, Russell C et al Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A Phase I—II study. J. Neurooncol 32, 45–55 (1997).
   PubMed Web of Science ®Google Scholar
• Buckner JC, Brown LD, Kugler JW et al Phase II evaluation of recombinant interferon-CL and BCNU in recurrent glioma. I Neurosurg. 82,430–435 (1995).
   PubMed Web of Science ®Google Scholar
• Yung WKA. Temozolomide in malignant gliomas. Semin. 0=1 27,27-34 (2000).
   Google Scholar
• Dinnes J, Cave C, Huang S, Milne R. A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma. Br.Cancer 86,501–505 (2002).
   Google Scholar
• Yung WYK, Prados MD, Yaya TR et al. Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytomas or anaplastic oligoastrocytoma at first relapse. j Gun. Oncol 17,2762–2771 (1999).
   Google Scholar
• Yung WYK, Albright RE, Olson J et al A Phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. BE j Cancer 83, 589–593 (2000).
   Google Scholar
• Wong ET, Hess KR, Gleason MJ et al Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J. Clin. 0=1 17, 2572–2578 (1999).
   Google Scholar
• Osoba D, Brada M, Yung WK, Prados MD. Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. Eur. Cancer36, 1788–1795 (2000).
   PubMed Web of Science ®Google Scholar
• Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA, Abrey LE. A Phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neurooncology 4,39–43 (2002).
   Google Scholar
• Newlands ES, Foster T, Zaknoen S. Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. BE j Cancer 89, 248–251 (2003).
   Google Scholar
• Korones DN, Benita-Weiss M, Coyle TE et al Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. Cancer 97,1963–1968 (2003).
   PubMed Web of Science ®Google Scholar
• Gilbert M, Wen P, Lieberman F et al Phase VII study of combination temozolomide (TMZ) and irinotecan (CPT-11) for recurrent malignant gliomas: a North American Brain Tumor Consortium (NABTC) study. Proc. Am. Soc. Clin. Oncol (2003) (Abstract 410).
   Google Scholar
• Gruber ML, Buster WP. Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma. Am. J. Clin. 0=1 27,33-38 (2004).
   Google Scholar
• Prados MD, Yung WKY, Fine HA et al. Phase II study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium Study. Neurooncology6, 33–37 (2004).
   PubMed Web of Science ®Google Scholar
• Jaeckle IKA, Hess KR, Yung WK et al Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium Study. j Clin. Oncol 21, 2305–2311 (2003).
   Google Scholar
• Groves MD, Puduvalli VK, Hess KR et al. Phase II trial of temozolomide plus the matrix met alloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. j Clin. 0=1 20,1383-1388 (2002).
   Google Scholar
• Silvani A, Eoli M, Salmaggi A et al. Phase II trial of cisplatin plus temozolomide in recurrent and progressive malignant glioma patients. I Neurooncol 66,203–208 (2004).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Basso U, Reni M et al First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a Phase II study of the Gruppo Italian° Co-operativo di Neuro-Oncologia. j Clin. 0=1 22, 1598–1604 (2004).
   Google Scholar
• Chua SL, Rosenthal MA, Wong SS et al Phase II study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme. Neurooncology6, 38–43 (2004).
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Gilbert MR, Supko JG et al Phase II study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neurooncology6, 21–27 (2004).
   PubMed Web of Science ®Google Scholar
• Houghton PJ. Cheshire PJ, Hallman JD et al Efficacy of the topoisomerase I inhibitors topotecan and irinotecan, administered in low doses in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol 36,393–403 (1995).
   PubMed Web of Science ®Google Scholar
• Buckner JC, Reid JM. Wright K et al Irinotecan in the treatment of glioma patients. Current and future treatments of the North Central Cancer Treatment Group. Cancer 97\(Suppl. 9), 2352–2358 (2003).
   Google Scholar
• Friedman HS, Petros WP, Friedman AH et al Irinotecan therapy in adults with recurrent or progressive malignant glioma. Clin. Oncol 17,1516–1525 (1999).
   Web of Science ®Google Scholar
• Prados MD, Yung WYK, Jaeckle IKA et al Phase I trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neurooncology6, 44–54 (2004).
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Supko JG, Batchelor T et al. Phase I clinical trial and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin. Cancer Res. 9, 2940–2949 (2003).
   PubMed Web of Science ®Google Scholar
• Raymond E, Fabbro M, Boige V et al Multicenter Phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastomas. Ann. Oncol 14,603–614 (2003).
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Filka E, Kuhn J et al Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen Cancer 1, 97(Suppl. 9), 2381–2386 (2003).
   Google Scholar
• Parker RJ, Fruehauf JP, Mehta R, Filka E, Cloughesy T A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma. I Neurooncol 66,365–375 (2004).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. j Neumoncol 56,183–188 (2002).
   PubMed Web of Science ®Google Scholar
• Reardon DA, Quinn JA, Rich JN et al Phase II trial of BCNU plus irinotecan in adults with malignant glioma. Neurooncology6, 134–144 (2004).
   PubMed Web of Science ®Google Scholar
• Jendrossek V, Belka C, Bamberg M. Novel chemotherapeutic agents for the treatment of glioblastoma multiforme. Expert Opin. Invest. Drugs 12,1899–1924 (2003).
   PubMed Web of Science ®Google Scholar
• Parney IF, Chang SM. Current chemotherapy for glioblastoma. Cancer 1 9,149–156 (2003).
   Google Scholar
• Weller M, Muller B, Koch R et al Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J. Clin. Oncol 21,3276–3284 (2003).
   Google Scholar
• Hau P, Fabel K, Baumgart U et al. Pegylated liposomal doxorubicin — efficacy in patients with recurrent high-grade glioma. Cancer100, 1199–1207 (2004).
   PubMed Web of Science ®Google Scholar
• Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann. Neural 23, 360–364 (1988).
   PubMed Web of Science ®Google Scholar
• Cairncross JG, Macdonald DR, Ludwin S et al Chemotherapy for oligodendroglioma. I Clin. Oncol 12, 2013–2021 (1994).
   PubMed Web of Science ®Google Scholar
• Soffietti R. Chemotherapy of anaplastic oligodendroglial tumours. Expert Opin. Pharmacother 5,295–306 (2004).
   PubMed Web of Science ®Google Scholar
• Glass J, Hochberg FH, Gruber ML, Louis DN, Smith D, Rattner B. The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. I Neurosurg. 76, 741–745 (1992).
   PubMed Web of Science ®Google Scholar
• Van Den Bent MJ. Guidelines for the treatment of oligodendroglioma: an evidence-based medicine approach. Forum (Genova)13,18–31 (2003).
   PubMedGoogle Scholar
• Paleologos NA, Caimcross JG. Treatment of oligodendrogliomas: an update. Neurooncology 1, 61–68 (1999).
   PubMedGoogle Scholar
• van den Bent M, Chinot OL, Caimcross JG. Recent developments in the molecular characterization and treatment of oligodendroglial tumors. Neurooncology5, 128–38 (2003).
   PubMed Web of Science ®Google Scholar
• •Good overview of the treatment and molecular genetics of oligodendrogliomas.
   Google Scholar
• Chinot O, Honore S, Barre M et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. j Clin. Oncol 19,2449–2455 (2001).
   PubMed Web of Science ®Google Scholar
• Van den Bent MJ, Chinot O, Boogerd W et al. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomusting and vincristine) chemotherapy: EORTC Brain Tumor Group Phase II study of 26972. Ann. Oncol 14,599–602 (2003).
   Google Scholar
• Van den Bent MJ, Taphoom MJB, Brandes AA et al Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglioma tumors: European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.1 Gun. Oncol 13, 2525–2528 (2003).
   Google Scholar
• Caimcross JG, Ueki K, Zlatescu MC et al Specific chromosomal losses predict chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. j Natl Cancer Inst. 90, 1473–1479 (1998).
   PubMedGoogle Scholar
• ••Landmark study showing loss ofchromosome lp and 19q is associated with improved survival and chemosensitivity in anaplastic oligodendrogliomas.
   Google Scholar
• InoY, Betensky RA, Zlatescu MC et al Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Gun. Cancer Res. 7,839–845 (2001).
   Web of Science ®Google Scholar
• •Important study that extends the association between loss of lp and 19q and improved prognosis and chemosensitivity.
   Google Scholar
• Brandes AA, Turazzi S, Basso U et al A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme. Neumlogy58, 1759–1764 (2002).
   PubMed Web of Science ®Google Scholar
• Quinn JA, Pluda J, Dolan ME et al Phase II trial of carmustine plus 06-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. I Gun. Oncol 20,2277–2283 (2002).
   Google Scholar
• Gururangan S, Cokgor L, Rich JN et al. Phase I study of Gliadel® wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neurooncology3, 246–250 (2001).
   PubMed Web of Science ®Google Scholar
• Westphal M, Lamszus K, Hilt D. Intracavitary chemotherapy for glioblastoma: present status and future directions. Acta Neumchir Suppl 88,61–67 (2003).
   PubMedGoogle Scholar
• Guerin C, Olivi A, Weingart JD et al Recent advances in brain tumor therapy: (2004).
   Google Scholar
• Brem H, Piantadosi S, Burger PC et al. Placebo-controlled trial of safety and chemotherapy for recurrent malignant gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345,1008–1012 (1999).
   Google Scholar
• Olivi A, Grossman SA, Tatter S et al Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches To Brain Tumor Therapy CNS Consortium trial.j Gun. Oncol 21, 1845–1849 (2003).
   Google Scholar
• Hassenbusch SJ, Nardone EM, Levin VA, Leeds N, Pietronigro D. Stereotactic injection of DTI-015 into recurrent malignant gliomas: Phase Jill trial. Neoplasia 5,9–16 (2003).
   Google Scholar
• Lidar Z, Mardor Y, Jonas T et al Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a Phase VII clinical study. Neurosurg. 100,472–479 (2004).
   Web of Science ®Google Scholar
• Menei P, Jadaud E, Faisant N et al. Stereotaxic implantation of 5-flurouracil-releasing microspheres in malignant glioma. A Phase I study. Cancer 100,405–410 (2004).
   Google Scholar
• Husain SR, Puri RK. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. Neumoncol 65,37–48 (2003).
   PubMed Web of Science ®Google Scholar
• Kunwar S, Prados M, Chang S et al. Peritumoral convection-enhanced delivery of IL-13-PE38QQR in patients with recurrent malignant glioma — Phase I interim results. Neumoncology5, 350 (2003) (Abstract TA–15).
   Google Scholar
• Kunwar S. Convection enhanced delivery of 1L13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing Phase I studies. Acta Neurochir. Suppl 88,105–111 (2003).
   Google Scholar
• Weber FVV, Floeth F, Asher A. Local convection enhanced delivery of 1L4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir. Suppl 88,93–103 (2003).
   Google Scholar
• Kawakami M, Kawakami K, Puri RK. Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy. Neurooncol 65(1), 15–25 (2003).
   Google Scholar
• Weber F, Asher A, Bucholz R et al Safety, tolerability, and tumor response of 1L4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. Neurooncol 64,125–137 (2003).
   PubMed Web of Science ®Google Scholar
• Sampson JH, Akabanai G, Archer GE et al Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-a and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. I Neurooncol 65, 27–35 (2003).
   PubMed Web of Science ®Google Scholar
• Mamelak AN, Raubitschek A, Morgan R et al A Phase VII trial of intracavitary 131I-TM-601 in adult patients with recurrent high-grade-glioma. Neurooncology 5,340 (2003) (Abstract RA–19).
   Google Scholar
• Maher EA, Fumari FB, Bachoo RM et al Malignant glioma: genetics and biology of a grave matter. Genes Dev. 15(11), 1311–1333 (2001).
   Google Scholar
• Kitange GJ, Templeton KL, Jenkins RB. Recent advances in the molecular genetics of primary gliomas. Curr Opin. Oncol 15(3), 197–203 (2003).
   Google Scholar
• Konopka G, Bonni A. Signaling pathways regulating gliomagenesis. Curr Mal Med 3(1), 73–84 (2003).
   PubMed Web of Science ®Google Scholar
• van den Boom J, Wolter M, Kuick R et al Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am. I Pathol 163,1033–1043 (2003).
   PubMed Web of Science ®Google Scholar
• Mischel PS, Nelson SF, Cloughesy TF. Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy. Cancer Biol. Ther 2, 242–247 (2003).
   Google Scholar
• Rao RD, Uhm JH, Krishnan S, James CD. Genetic and signaling pathway alterations in glioblastoma: relevance to novel targeted therapies. Front. Biosci 8,270–280 (2003).
   Web of Science ®Google Scholar
• Shai R, Shi T, Kremen TJ et al Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 22,4918–4923 (2003).
   PubMed Web of Science ®Google Scholar
• Nutt CL, Mani DR, Betensky RA et al Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 63,1602–1607 (2003).
   PubMed Web of Science ®Google Scholar
• Drucker BJ. Perspectives on the development of a molecularly targeted agent. Cancer Cell 1, 31–36 (2002).
   PubMed Web of Science ®Google Scholar
• Karpati G, Nalbantoglu J. The principles of molecular therapies for glioblastoma. Int. Rev Neumbiol 55,151–163 (2003).
   PubMed Web of Science ®Google Scholar
• Newton FIB. Molecular neuro-oncology and the development of 'targeted' therapeutic strategies for brain tumors. Part 1 — growth factor and Ras signaling pathways. Expert Rev. Anticancer Ther. 3, 595–614 (2003).
   Google Scholar
• •Comprehensive review of targeted molecular therapies for brain tumors.
   Google Scholar
• Newton HB. Molecular neurooncology and the development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis. Expert Rev Anticancer Ther. 4,105-128 (2004).
   Google Scholar
• •Comprehensive review of targeted molecular therapies for brain tumors.
   Google Scholar
• Mischel PS, Cloughesy TF. Targeted molecular therapy of glioblastoma. Brain Pathol 13,52–61 (2003).
   PubMed Web of Science ®Google Scholar
• Rich JN, Bigner DD. Development of novel targeted therapies in the treatment of malignant glioma. Nature Rev Drug Discov 3,430–446 (2004).
   PubMed Web of Science ®Google Scholar
• •Recent review of targeted molecular therapy.
   Google Scholar
• Tremont-Lukats IW Gilbert MR. Advances in molecular therapies in patients with brain tumors. Cancer Control10, 125–137 (2003).
   Google Scholar
• Jendrossek V, Belka C, Bamberg M. Novel chemotherapeutic agents for the treatment of glioblastoma multiforme. Expert Opin. Invest. Drugs 12,1899–1924 (2003).
   PubMed Web of Science ®Google Scholar
• Rich J, Reardon DA, Peery TS et al Phase II trial of ZD1839 for patients with first relapse glioblastoma. j Clin. Oncol 22, 133–142 (2004).
   Google Scholar
• Shinojima N, Tada K, Shiraishi S et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 63,6962–6970 (2003).
   PubMed Web of Science ®Google Scholar
• Lieberman F, Cloughesy T, Deangelis LM et al Phase I—II study of ZD-1839 for recurrent malignant gliomas and meningiomas progressing after radiation therapy. Pmc. Am. Soc. Clin. Oncol. (2004) (Abstract 1510).
   Google Scholar
• Uhm JH, Ballman KV, Giannini JC et al Phase II study of ZD1839/Iresse in patients with newly diagnosed grade 4 astrocytoma. Proc. Am. Soc. Clin. Oncol. (2004) (Abstract 1505).
   Google Scholar
• Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl. I Merl 350, 2129–2139 (2004)
   PubMed Web of Science ®Google Scholar
• Raizer JJ, Abrey L, Wen P et al A Phase II trial of OSI-774 (Tarceva) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs. Proc. Am. Soc. Clin. Oncol. (2004) (Abstract 1502).
   Google Scholar
• Prados M, Chang S, Burton E et al Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma. Proc. Am. Soc. Clin. Oncol (2003) (Abstract 394).
   Google Scholar
• Vogelbaum MA, Peereboom D, Stevens G et al Phase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent glioblastoma multiforme: interim results. Proc. Am Soc. Clin. Oncol (2004) (Abstract 1558).
   Google Scholar
• Goudar R, Keir S, Hjelmeland M et al Combination therapy of inhibitors of the epidermal growth factor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma growth inhibition. AACR-NCI-EORTC Int. Con( Mol. Targets Cancer Ther. (2003) (Abstract A88).
   Google Scholar
• Guha A, Dashner K, Black PM et al. In vivo expression of PDGF and PDGF receptors in human astrocytomas. int. Cancer 60,168–173 (1995).
   PubMed Web of Science ®Google Scholar
• Kilic T, Alberta J, Zdunek PR et al Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally-active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. 60,5143–5150 (2000).
   PubMed Web of Science ®Google Scholar
• Wen PY, Yung WK, Hess K et al. Phase I study of 5TI571 (Gleevec) for patients with recurrent malignant gliomas and meningiomas (NABTC 99–08). Proc. Am. Soc. Clin. Oncol 73a (2002) (Abstract 291).
   Google Scholar
• Raymond E, Brandes A, Van Oosterom AV et al Multicentre Phase II study of imatinib mesylate (Glivec®) in patients with recurrent glioblastoma: an EORTC/ NDDG/BTG Intergroup study. Proc. Am. Soc. Clin. Oncol (2004) (Abstract 1501).
   Google Scholar
• Dai H, Marbach P, Lemaire M et al. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. Pharmacol Exp. Ther. 304,1085-1092 (2003).
   Google Scholar
• Dresemann G. Imatinib (5TI571) plus hydroxyurea: safety and efficacy in pretreated, progressive glioblastoma multiforme (GBM) patients (pts). Proc. Am. Soc. Clin. Oncol (2004) (Abstract 1550).
   Google Scholar
• de Bono JS, Tolcher AW, Rowinsky EK. Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma. Semin. Oncol. 30(5 Suppl. 16), 79–92 (2003).
   Google Scholar
• Cloughesy TF, Kuhn J, Wen P et al. Two Phase II trials of R115777 (Zarnestre) in patients with recurrent glioblastoma multiforme: a comparison of patients on enzyme-inducing antiepileptic drugs (EIAED) and not on EIAED at maximum tolerated dose respectively: a North American Brain Tumor Consortium (NATC) report. Neurooncology5, 349 (2003) (Abstract TA–10).
   Google Scholar
• Mita MM, Mita A, Rowinsky EK. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol. Ther 2(4 Suppl. 1), S169—S177 (2003).
   Google Scholar
• Geoerger B, Kerr K, Tang C-B et al Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res. 61,1527–1532 (2001).
   PubMed Web of Science ®Google Scholar
• Chang S, Kuhn J, Wen P et al Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest. New Drugs 22 (4), 427–435 (2004).
   Google Scholar
• Chang S, Kuhn J, Wen P et al Phase II/pharmacokinetic study of CCI-779 in recurrent glioblastoma multiforme. Society for Neuro-Oncology 8th annual meeting. Neumoncology5, 349 (2003) (Abstract TA–09).
   Google Scholar
• Galanis E, Buckner JC, Maurer K et al. NCCTG Phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM). Proc. Am. Soc. Clin. Oncol (2004) (Abstract 1503).
   Google Scholar
• Readon D, Friedman H, Yung WKA et al. A Phase I trial of PTK787/ZK 222584 (PTIQZK), an oral VEGF tyrosine kinase inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). Floc. Am. Soc. Clin. Dried (2004) (Abstract 1513).
   Google Scholar
• Marks PA, Rifkind RA, Richon VM et al. Histone deacetylases and cancer: causes and therapies. Nature Cancer Rev. 1,194–202 (2001).
   PubMed Web of Science ®Google Scholar
• Rubin JB, Kung AL, Klein RS et al A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc. Natl Acad. Sci. 100, 13513–13518 (2003).
   Google Scholar
• Guzman M. Cannabinoids: potential anticancer agents. Nature Rev Cancer 3, 745–755 (2003).
   PubMed Web of Science ®Google Scholar
• Sanchez C, de Ceballos ML, del Pulgar TG et al. Inhibition of glioma growth in vivo by selective activation of the CB (2) cannabinoid receptor. Cancer Res. 61, 5784–5789 (2001).
   Google Scholar
• Choe G, Horvath S, Cloughesy TF et al. Analysis of the phosphatidylinositol 3--kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 63,2742–2746 (2003).
   PubMed Web of Science ®Google Scholar
• Tjuvajev JG, Blasberg R. In vivo imaging of molecular-genetic targets for cancer therapy. Cancer Ce113, 327–332 (2003).
   Google Scholar
• Kieran MW, Billett A. Anti-angiogenesis therapy. Current and future agents. Hematol. Oncol. Clin. North Am. 15, 835–851 (2001).
   PubMed Web of Science ®Google Scholar
• Bogler O, Mikkelsen T Angiogenesis in glioma: molecular mechanisms and roadblocks to translation. Cancer 1 9, 205–213 (2003).
   Google Scholar
• •Concise review of angiogenesis in glioma.
   Google Scholar
• Kieran MW. Anti-angiogenic chemotherapy in central nervous system tumors. Cancer 7i-eat. Res. 117,337-349 (2004).
   Google Scholar
• Castro MG, Cowen R, Williamson IK. Current and future strategies for the treatment of malignant brain tumors. Pharmacol Ther. 98,71–108 (2003).
   Google Scholar
• Basso U, Ermani M, Vastola F, Brandes AA. Non-cytotoxic therapies for malignant gliomas. I Neurooncol. 58,57–68 (2002).
   PubMed Web of Science ®Google Scholar
• Fine HA, Figg WD, Jaeclde K et al Phase II trial of the anti-angiogenic agent thalidomide in patients with recurrent high-grade gliomas. j Clin. Oncol 18, 708–715 (2000).
   PubMed Web of Science ®Google Scholar
• Marx GM, Pavlakis N, McCowatt S et al. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. j Neurooncol 54,31–38 (2001).
   PubMed Web of Science ®Google Scholar
• Short SC, Traish D, Dowe A, Hines F, Gore M, Brada M. Thalidomide as an anti-angiogenic agent in relapsed gliomas. Neumoncol 51,41–45 (2001).
   PubMed Web of Science ®Google Scholar
• Fine HA, Wen PY, Maher EA et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade-gliomas. j Clin. Oncol 21, 2299–2304 (2003).
   PubMed Web of Science ®Google Scholar
• Groves MD, Tremont-Lukats IW, Conrad C et al. A Phase II trial of temozolomide plus thalidomide (NABTC 99–04) for recurrent malignant glioma. Proceedings of the 5th Congress of the European Association for Neuro-Oncology. Neurooncology 4, S41 (2002).
   Google Scholar
• Fine HA, Kim L, Royce C et al A Phase II trial of LY317615* in patients with recurrent high grade gliomas. Proc. Am. Soc. Clin. Oncol (2004) (Abstract 1511).
   Google Scholar
• Jones MK, Wang H, Peskar BM et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nature Med. 5, 1418–1423 (1999).
   PubMed Web of Science ®Google Scholar
• Masferrer JL, Leahy KM, Koki AT et al. Anti-angiogenic and antitumor activities of cyclooxygenaase-2 inhibitors. Cancer Res. 60,1306–1311 (2000).
   PubMed Web of Science ®Google Scholar
• Joki T, Heese O, Nikas DC et al Expression of cyclooxygenase-2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res. 60,4926–4931 (2000).
   PubMed Web of Science ®Google Scholar
• Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FE Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res. 61,4375–4381 (2001).
   PubMed Web of Science ®Google Scholar
• Giglio P, Levin V. Cyclooxygenase-2 inhibitors in glioma therapy. Am. J. Ther. 11,141-143 (2004).
   Google Scholar
• Badie B, Schartner JM, Hagar AR et al. Microglia cyclooxygenase-2 activity in experimental gliomas: possible role in cerebral edema formation. Clin. Cancer Res. 9,872-877 (2003).
   Google Scholar
• Lamszus K, Kunkel P, Westphal M. Invasion as limitation to anti-angiogenic glioma therapy. Acta Neurochir. Sup* 88, 169–177 (2003).
   Google Scholar
• Chatteijee S, Matsumura A, Schradermeier J, Gillespie GY. Human malignant glioma therapy using anti-a(v) 03 integrin agents. Neurooncol 46,135–144 (2000).
   PubMed Web of Science ®Google Scholar
• MacDonald TJ, Taga T, Shimada H et al. Preferential susceptibility of brain tumors to the anti-angiogenic effects of an a (v) integrin antagonist. Neurosurgery 48, 151–157 (2001).
   PubMed Web of Science ®Google Scholar
• Browder T, Butterfield CE, Kraling BM et al. Anti-angiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60,1878–1886 (2000).
   PubMed Web of Science ®Google Scholar
• Wen PY, Schiff D, MacDonald L et al. Phase II study of anti-angiogenic chemotherapy for recurrent malignant glioma. Neurooncology 4, 357 (2004) (Abstract TA 42).
   Google Scholar
• See SJ, Levin VA, Yung WK, Hess KR, Groves MD. 13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme. Neurooncology 6 (3), 253–258 (2004).
   Google Scholar
• Yung WYK, Kyritsis AP, Gleason MJ, Levin VA. Treatment of recurrent malignant gliomas with high-dose 13 cis-retinoic acid. Clin. Cancer Res. 2, 1931–1935 (1996).
   Google Scholar
• Puduvalli VK, Yung WKA, Hess KR et al. A Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: a North American Brain Tumor Consortium (NABTC) study. J. Clin. Oncol (2004) (In Press).
   Google Scholar
• Chang SM, Kuhn JG, Ian Robins H et al. A study of a different dose-intense infusion schedule of phenylacetate in patients with recurrent primary brain tumors consortium report. Invest. New Drugs. 21,429–433 (2003).
   Google Scholar
• Couldwell WT, Weiss MH, DeGiorgio CM et al. Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neumsurgety32, 485–489 (1993).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Kormanik PA. Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas. Arch. Neuml. 56, 703–708 (1999).
   PubMed Web of Science ®Google Scholar
• Hercbergs AA, Goyal LK, Suh JH et al Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a Phase I/II study. Anticancer Res 23,617–626 (2003).
   PubMed Web of Science ®Google Scholar
• Rainov NG, Ren H. Clinical trials with retrovirus mediated gene therapy — what have we learned?J Neurooncol 65, 227–236 (2003).
   PubMed Web of Science ®Google Scholar
• •Good overview of retroviral gene therapy.
   Google Scholar
• Shah AC, Benos D, Yancey Gillespie G, Markert JM. Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. I Neurooncol 65, 203–226 (2003).
   PubMed Web of Science ®Google Scholar
• •Comprehensive overview of oncolytic viruses.
   Google Scholar
• Vecil GG, Lang FE Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses. Neumoncol 65,237–246 (2003).
   PubMed Web of Science ®Google Scholar
• Laura K, Aguilar LK, Aguilar-Cordova E. Evolution of a gene therapy clinical trial. From bench to bedside and back. J Neurooncol 65,307–315 (2003).
   Google Scholar
• Kanzawa T, Ito H, Kondo Y, Kondo S. Current and future gene therapy for malignant gliomas. j Biomed Biotech. 1, 25–34 (2003).
   Google Scholar
• Rainov NG, Ren H. Gene therapy for human malignant brain tumors. Cancer 9,180–188 (2003).
   Web of Science ®Google Scholar
• Post DE, Fulci G, Chiocca EA, Van Meir EG. Replicative oncolytic herpes simplex viruses in combination cancer therapies. Curr Gene Ther. 4,41–51 (2004).
   Google Scholar
• Ram Z, Culver KW Oshiro EM et al Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nature Med. 12, 1354–1361 (1997).
   Google Scholar
• Prados MD, McDermott M, Chang SM et al Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a Phase VII multi-institutional trial. Neumoncol 65,269–278 (2003).
   PubMed Web of Science ®Google Scholar
• Smitt PS, Driesse M, Wolbers J, Kros M, Avezaat C. Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir. Mal Ther. 7,851–858 (2003).
   Google Scholar
• Germano IM, Fable J, Gultekin SH, Silvers A. Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a Phase I trial in patients with recurrent malignant gliomas. Neurooncol 65(3), 279–89 (2003).
   PubMed Web of Science ®Google Scholar
• Lang FF, Bruner JM, Fuller GN et al Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin. Oncol 21,2505–2518 (2003).
   Google Scholar
• Lichtor T, Glick RP. Cytokine immunogene therapy for treatment of brain tumors. Neurooncol 65,247–259 (2003).
   PubMed Web of Science ®Google Scholar
• Eck SL, Alavi JB, Judy K et al Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferon-13 (H5 .010CMVION-13): a Phase I trial. Human Gene Ther. 12, 97–113 (2001).
   Google Scholar
• Markert JM, Medlock MD, Rabkin SD et al Conditionally replicating herpes simplex virus mutant, G207, for the treatment of malignant glioma: results of a Phase I trial. Gene Ther 7,867–874 (2000).
   PubMed Web of Science ®Google Scholar
• Wilcox ME, Yang W, Senger D et al Reovirus as an oncolytic agent against experimental human malignant gliomas. I Natl Cancer Inst. 93,903–912 (2001).
   PubMed Web of Science ®Google Scholar
• Yang L, Ng KY, Lillehei KO. Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma. Cancer Contro110, 138–147 (2003).
   Google Scholar
• Fecci PE, Sampson JH. Clinical immunotherapy for brain tumors. Neuroimaging Clin. N. Arn. 12,641–664 (2002).
   PubMed Web of Science ®Google Scholar
• Fecci PE, Mitchell DA, Archer GE et al The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. Neurooncol 64,161–176 (2003).
   PubMed Web of Science ®Google Scholar
• Paul DB, Kruse CA. Immunologic approaches to therapy for brain tumors. Curr. Neural Neumsci. Rep. 1,238–244 (2001).
   PubMedGoogle Scholar
• Fenstermaker RA, Ciesielski MJ. Immunotherapeutic strategies for malignant glioma. Cancer Contm111, 181–191 (2004).
   Google Scholar
• Ehtesham M, Black KL, Yu JS. Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials. Cancer Control 11, 192–197 (2004).
   PubMedGoogle Scholar
• Goetz C, Riva P, Poepperl G et al Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times. Neurooncol 62,321–328 (2003).
   PubMed Web of Science ®Google Scholar
• Quang TS, Brady LW Radioimmuno- therapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int. J Radiat. Oncol Biol. Phys. 58, 972–975 (2004).
   Google Scholar
• Paganelli G, Bartolomei M, Ferrai M et al Pretargeted radioimmunotherapy with 90Y-biotin in glioma patients: Phase I study and preliminary therapeutic results. Cancer Biother. Radiopharm. 16,227-235 (2001).
   Google Scholar
• Yamanaka R, Abe T, Yajima N et al Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical Phase I/II trial. Br. J. Cancer 89, 1172–1179 (2003).
   PubMed Web of Science ®Google Scholar
• Yu JS, Wheeler CJ, Zeltzer PM et al Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 61,842–847 (2001).
   PubMed Web of Science ®Google Scholar
• Okada H, Lieberman FS, Edington HD et al Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy. Neumoncol 64,13–20 (2003).
   PubMed Web of Science ®Google Scholar
• Bogdahn U, Hau P, Brawanski A et al Specific therapy for high-grade glioma by convection-enhanced delivery of the TGF-02 specific antisense oligonucleotide AP 12009. Proc. Am. Soc. Clin. Oncol (2004) (Abstract 1514).
   Google Scholar
• Reni M, Brandes AA. Current management and prognostic factors for adult ependymoma. Expert Rev Anticancer Ther 2,537–545 (2002).
   PubMedGoogle Scholar
• Chamberlain MC. Ependymomas. Curl: Neural Neurosci. Rep. 3,193–199 (2003).
   Google Scholar
• Moynihan TJ. Ependymal tumors. Cud: Treat. Options Oncol 4,517–523 (2003).
   PubMedGoogle Scholar
• Prados MD, Yung WKA, Wen P et al. Phase I study of ZD1839 plus temozolomide in patients with malignant glioma. A study of the North American Brain Tumor Consortium. Proc. Am. Soc. Clin. Oncol (2004) (Abstract 1504). Affiliations
   Google Scholar